Evidence of the Immunomodulatory Effects of Selective Serotonin Reuptake Inhibitors in Patients With Depression Through a Systematic Review

被引:0
作者
Patel, Ankit N. [1 ]
Varma, Jagdish [2 ]
Ganguly, Barna [1 ]
机构
[1] Pramukhswami Med Coll, Pharmacol, Karamsad, India
[2] Pramukhswami Med Coll, Psychiat, Karamsad, India
关键词
immunomodulatory effect; depression; crp; tnf-alpha; il-6; antidepressant; ssri; C-REACTIVE PROTEIN; ANTIDEPRESSANT TREATMENT; INFLAMMATORY CYTOKINES; TREATMENT RESPONSE; DISORDER; INTERLEUKIN-6; FLUOXETINE; METAANALYSIS; ESCITALOPRAM; LEVEL;
D O I
10.7759/cureus.62991
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Depression is a common illness, affecting >264 million people worldwide. According to the literature, depression patients have baseline subclinical inflammation. The immunomodulatory effects of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), are largely unclear and poorly understood. Using evidence-based medicine, this study aimed to determine the immunomodulatory effects of SSRIs by assessing changes in immunomodulatory markers following SSRI treatment. Using the PubMed website, a literature search was conducted with various terminologies related to the treatment of depression and various markers of inflammation. Out of 387 retrieved articles, after critical appraisal and screening based on inclusion and exclusion criteria, 17 were selected. Qualitative synthesis and quantitative analysis were carried out. RevMan 5 software was used to synthesize and evaluate the data. Microsoft Word and Excel (Microsoft Corporation, Redmond, Washington, United States) were used for generating tables and figures. We extracted data from a total of 839 patients in 17 studies. A highly significant reduction in interleukins-6 (IL-6) (standardised mean difference (SMD) = 1.32 (95% confidence interval (CI): 0.58, 2.06), Z = 3.48, P = 0.0005), a significant reduction in tumor necrosis factor-alpha (TNF-alpha) (SMD = 1.29 (95% CI: 0.19, 2.39), Z = 2.30, P = 0.02) but no change in overall C-reactive protein (CRP) (SMD = 0.40 (95% CI: -0.26, 1.07), Z = 1.19, P = 0.23) levels were observed by using the random-effects model. There was substantial heterogeneity found between the studies. SSRIs have an immunomodulatory effect in patients with depression by significantly reducing the peripheral pro-inflammatory cytokine markers of IL-6 and TNF-alpha, which may contribute to ameliorating the response to antidepressant drug treatment. In contrast, no effects of SSRIs on acute-phase protein CRP were found.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Selective Serotonin Reuptake Inhibitors: A Review of its Effects on Intraocular Pressure
    Costagliola, Ciro
    Parmeggiani, Francesco
    Semeraro, Francesco
    Sebastiani, Adolfo
    CURRENT NEUROPHARMACOLOGY, 2008, 6 (04) : 293 - 310
  • [22] Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients
    Worthington, JJ
    Kinrys, G
    Wygant, LE
    Pollack, MH
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (01) : 9 - 11
  • [23] Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies
    Barbui, Corrado
    Esposito, Eleonora
    Cipriani, Andrea
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2009, 180 (03) : 291 - 297
  • [24] The effect of selective serotonin reuptake inhibitors in healthy subjects. A systematic review
    Knorr, Ulla
    Kessing, Lars Vedel
    NORDIC JOURNAL OF PSYCHIATRY, 2010, 64 (03) : 153 - 163
  • [25] Selective serotonin reuptake inhibitors for depression in pregnancy
    Susser, Leah C.
    Sansone, Stephanie A.
    Hermann, Alison D.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 215 (06) : 722 - 730
  • [26] A systematic review and meta-analysis on the effect of selective serotonin reuptake inhibitors on endothelial function
    Delialis, Dimitrios
    Mavraganis, Georgios
    Dimoula, Anna
    Patras, Raphael
    Dimopoulou, Angeliki-Maria
    Sianis, Alexandros
    Ajdini, Erold
    Maneta, Eleni
    Kokras, Nikolaos
    Stamatelopoulos, Kimon
    Georgiopoulos, Georgios
    JOURNAL OF AFFECTIVE DISORDERS, 2022, 316 : 71 - 75
  • [27] Analysis of the Effects of Selective Serotonin (and Noradrenaline) Reuptake Inhibitors on the Risk of Dementia in Patients with Depression
    Kostev, Karel
    Bohlken, Jens
    Jacob, Louis
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 69 (02) : 577 - 583
  • [28] The pharmacogenomics of selective serotonin reuptake inhibitors
    Garcia-Marin, Luis M.
    Rabinowitz, Jill A.
    Ceja, Zuriel
    Alcauter, Sarael
    Medina-Rivera, Alejandra
    Renteria, Miguel E.
    PHARMACOGENOMICS, 2022, 23 (10) : 597 - 607
  • [29] Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta-analysis
    Liu, Yiyun
    Zhou, Xinyu
    Zhu, Dan
    Chen, Jianjun
    Qin, Bin
    Zhang, Yuqing
    Wang, Xiao
    Yang, Deyu
    Meng, Huaqing
    Luo, Qinghua
    Xie, Peng
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2015, 30 (03) : 132 - 142
  • [30] Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review
    Le, Gia Han
    Wong, Sabrina
    Lu, Andy
    Vasudeva, Shreya
    Gill, Hartej
    Badulescu, Sebastian
    Portelles, Daylen Rodriguez
    Zheng, Yang Jing
    Teopiz, Kayla M.
    Meshkat, Shakila
    Kwan, Angela T. H.
    Ho, Roger
    Rhee, Taeho Greg
    Rosenblat, Joshua D.
    Mansur, Rodrigo B.
    McIntyre, Roger S.
    JOURNAL OF AFFECTIVE DISORDERS, 2025, 368 : 798 - 819